Independent peptide education · Evidence annotated · Research use information
Peptide Library / Melanotan II

Melanotan II Research Guide

Synthetic melanocortin receptor agonist

Limited human evidence
ClassificationSingle Peptide
Evidence tierLimited human evidence
Research statusEducational reference
01 · At a glance

Overview

Melanotan II is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.

Dosing & reconstitution guide

Melanotan II suggested dosing guide

A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.

Research protocol only
Suggested starting rangeNo approved human dose
Typical reference range250–500 mcg commonly discussed
FrequencyDaily during nonclinical loading protocols
TimingOften in the evening because nausea can occur
Typical durationVariable; maintenance protocols are anecdotal
RouteSubcutaneous injection

Titration and protocol notes

Start-low approaches are commonly discussed, but safety and long-term risk are not established.

Annotated dosage protocol

Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.

PhaseDoseScheduleWhat this dosage means
Lower referenceNo approved human doseDaily during nonclinical loading protocolsThe lower end reported in research discussions; it is not a validated human starting prescription.
Commonly cited range250–500 mcg commonly discussedOften in the evening because nausea can occurA range repeated in reference protocols. Repetition does not establish safety, efficacy, or an approved regimen.
Duration / reassessmentVariable; maintenance protocols are anecdotalReassess before continuingStart-low approaches are commonly discussed, but safety and long-term risk are not established. Dose changes should never be inferred from vial size or convenient syringe units.

Melanotan II reconstitution example

This worked example uses a 10 mg vial, 2 mL of diluent, and a 250 mcg reference amount.

Vial strength10 mg
Diluent added2 mL
Concentration5 mg/mL
Example draw0.05 mL / 5 units
How this example is calculated: 10 mg ÷ 2 mL = 5 mg/mL. The 250 mcg reference amount equals 0.25 mg. That produces a 0.05 mL draw, or 5 units on a U-100 syringe.

Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.

Safety, handling, and storage
  • Suggested ranges are educational summaries, not individualized prescriptions.
  • FDA-labeled regimens apply only to the approved product, indication, and delivery system.
  • For experimental compounds, human safety, purity, and effective dosing may be unknown.
  • Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Live concentration math

Melanotan II calculator

Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.

Runs in your browser
Concentration5 mg/mL
Draw volume0.05 mL
On the syringe5 units
Portions per vial40

Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.

02 · How it is studied

Mechanism and research rationale

A cyclic analog of alpha-MSH that activates multiple melanocortin receptors and has been studied for pigmentation and other melanocortin-mediated effects.

Melanocortin signaling

Pigmentation

Sexual-function research

03 · Interpretation

Key facts

  • Evidence tier: Limited human evidence.
  • Research status and regulatory status are not interchangeable.
  • This page is an educational reference and does not provide personal medical instructions.
04 · Editorial annotations

What to keep in mind

Editorial note: distinguish peer-reviewed findings from supplier or community claims.
Evidence note: study design, species, route and formulation can materially change interpretation.
05 · Sources

References and evidence indexes

  1. PubMed search: Melanotan II
  2. ClinicalTrials.gov search
Research product

Looking for Melanotan II?

View the corresponding Melanotan-II (MT-2) research product, specifications, and available documentation from Novatherix Laboratories.

View at Novatherix →

External catalog link. For qualified laboratory and research use only.

Research notice: This guide is educational and not medical advice. It does not diagnose, treat, prescribe, or recommend personal use.